Cargando…

Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells

PURPOSE: The current study aimed to investigate the synergistic antitumor effect of combined treatment with 17-DMAG (HSP90 inhibitor) and NVP-BEZ235 (PI3K/mTOR dual inhibitor) on cisplatin-resistant human bladder cancer cells. MATERIALS AND METHODS: Human bladder cancer cells exhibiting cisplatin re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyung Joon, Gong, Mi Kyung, Yoon, Cheol Yong, Kang, Jaeku, Yun, Mijin, Cho, Nam Hoon, Rha, Sun Young, Choi, Young Deuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329736/ https://www.ncbi.nlm.nih.gov/pubmed/32608202 http://dx.doi.org/10.3349/ymj.2020.61.7.587

Ejemplares similares

Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
por: Chen, Ming-Huang, et al.
Publicado: (2014)

Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma
por: Bekki, Hirofumi, et al.
Publicado: (2015)

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells
por: MOON, DU G., et al.
Publicado: (2014)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell
por: Zhu, Hao, et al.
Publicado: (2020)

In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458
por: Albawardi, Alia, et al.
Publicado: (2014)

Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer
por: Mrozek, Evelyn M., et al.
Publicado: (2021)

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
por: Wu, Chunjing, et al.
Publicado: (2005)

RF07 | PSUN356 Synergistic Combination of HSP90 and PI3K inhibitors in Adrenocortical Cancer
por: Mishra, Prachi, et al.
Publicado: (2022)

Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors
por: Rodrigues Moita, Ana J., et al.
Publicado: (2020)

Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule
por: Djuzenova, Cholpon S., et al.
Publicado: (2016)

Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib
por: Mortensen, Anja Charlotte Lundgren, et al.
Publicado: (2020)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Cancer cell responses to Hsp70 inhibitor JG-98: Comparison with Hsp90 inhibitors and finding synergistic drug combinations
por: Yaglom, Julia A., et al.
Publicado: (2018)

HSP-90 Inhibitor Ganetespib is Synergistic with Doxorubicin in Small Cell Lung Cancer
por: Lai, Chien-Hao, et al.
Publicado: (2013)

Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma
por: Yu, Seong-Lan, et al.
Publicado: (2018)

Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells
por: ZITZMANN, KATHRIN, et al.
Publicado: (2013)

HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy
por: Lin, Tzu-yin, et al.
Publicado: (2016)

Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures
por: Daunys, Simonas, et al.
Publicado: (2019)

Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
por: Blaser, Benjamin, et al.
Publicado: (2012)

Author Correction: Cancer cell responses to Hsp70 inhibitor JG-98: Comparison with Hsp90 inhibitors and finding synergistic drug combinations
por: Yaglom, Julia A., et al.
Publicado: (2018)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Engineering prodrug nanomicelles as pyroptosis inducer for codelivery of PI3K/mTOR and CDK inhibitors to enhance antitumor immunity
por: Yang, Qichao, et al.
Publicado: (2022)

The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer
por: Roh, J-L, et al.
Publicado: (2013)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines
por: Subtil, Florentine S. B., et al.
Publicado: (2022)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth
por: Soliman, Ghada A, et al.
Publicado: (2020)

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
por: Kim, Hyera, et al.
Publicado: (2020)

Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells
por: Reita, Damien, et al.
Publicado: (2019)

A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors
por: Yang, Shujie, et al.
Publicado: (2011)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
por: Proia, David A., et al.
Publicado: (2012)

Apoptosis and antitumor effects induced by the combination of an mTOR inhibitor and an autophagy inhibitor in human osteosarcoma MG63 cells
por: HORIE, RYOSUKE, et al.
Publicado: (2015)

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
por: Shoji, Keiko, et al.
Publicado: (2012)

Migration pattern, actin cytoskeleton organization and response to PI3K-, mTOR-, and Hsp90-inhibition of glioblastoma cells with different invasive capacities
por: Memmel, Simon, et al.
Publicado: (2017)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l4f4pbo90vtnio1nou75bl4s24